Skip to content

Exploring the mechanism of sleep disorders and the therapeutic prospect of neuroregulation techniques

Exploring the mechanism of sleep disorders and the therapeutic prospect of neuroregulation techniques

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097750
Enrollment
Unknown
Registered
2025-02-25
Start date
2025-02-25
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep disorder

Interventions

Intervention treatment group:Different TMS treatment regimens were used, 5 times a week for a total of 4 weeks
Control group:None

Sponsors

Zhongshan Hospital and Xiamen Hospital affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 79 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for patients with chronic insomnia 1. Age 18-79 years old. 2. Meet the diagnostic criteria for chronic insomnia in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), with a baseline PSQI score of > 6. 3. No other sleep disorders (such as sleep-related movement disorders, excessive sleepiness or sleep abnormalities); 4. No change in medication taken within 4 weeks before treatment; 5. Voluntarily signed written informed consent. Inclusion criteria for the healthy control group 1. Age 18-79 years old; 2. Denial of a history of sleep disturbance (PSQI score < = 5 points); 3. Denial of a history of neurological or psychiatric disorders, such as depressive states or anxious states, etc.

Exclusion criteria

Exclusion criteria: 1. Those with a history of epilepsy or severe head trauma, implanted medical devices (such as pacemakers, in-ear hearing aids, etc.), or pregnancy. 2. Severe neurological or psychiatric illness or medical condition (such as skull defect and craniotomy) or other conditions that may affect sleep. 3. Serious liver, kidney, cardiovascular and cerebrovascular, hematopoietic system diseases and other serious complications. 4. Heavy alcohol abuse and drug abuse (including sleeping pills). 5. Unable to cooperate with the completion of treatment, unable to complete MRI and neuropsychological evaluation.

Design outcomes

Primary

MeasureTime frame
Sleep quality;

Secondary

MeasureTime frame
Sleep-related moods;

Countries

China

Contacts

Public ContactJinyue Li

Zhongshan Hospital and Xiamen Hospital affiliated to Fudan University

li.jinyue@zsxmhospital.com+86 159 6080 3380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026